Skip to main content
Premium Trial:

Request an Annual Quote

S2 Genomics, Riken Partner on Single-Cell Genomics Applications

NEW YORK – S2 Genomics said on Tuesday that Japan's RIKEN Center for Integrated Medical Sciences will evaluate and further develop single-cell sequencing applications on the S2 Genomics' Singulator tissue prep system under and early-access program.  

According to Livermore, California-based S2 Genomics, the Singulator platform combines enzymatic and mechanical disruption to produce suspensions of cells or nuclei for downstream single-cell applications.

S2 Genomics plans to commercially launch the platform later this year as a research-use-only instrument.

"The Singulator automates and standardizes the dissociation of solid tissues and can improve the quality of single-cell and single-nuclei data from a variety of solid tissue types," S2 Genomics CEO and President Stevan Jovanovich said in a statement. "We are excited to work with the RIKEN IMS to evaluate the performance of the system and to develop new applications for the Singulator platform."

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.